Cite
MLA Citation
Fabian Trillsch et al.. “2022-RA-835-ESGO AGO-OVAR 2.34/MIROVA: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy.” International journal of gynecological cancer, vol. 32, n.d., p. A268. http://access.bl.uk/ark:/81055/vdc_100168339599.0x00002f